Home » Newsletters » BioWorld

BioWorld

April 3, 1992

View Archived Issues

BIOMIRA MOVES DIAGNOSTICS INTO AFFILIATE

GTII LICENSES CYTOKINE FROM CISTRON

PURIFICATION COMPANY FILES FOR IPO

HOLDING COMPANY SPINOFF FILES IPO

HATFIELD DROPS PATENT BILL AFTER CONCESSIONS

RIBI PLACEMENT RAISES $11 MILLION

FDA APPROVES IMPROVED HYCOR TEST

IMMUNEX CHARGES HOECHST WITH GM-CSF DUMPING

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...